Cargando…
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
Broadly neutralizing antibodies (bNAbs) are promising agents to prevent HIV infection and achieve HIV remission without antiretroviral therapy (ART). As with ART, bNAb combinations are likely needed to cover HIV’s extensive diversity. Not all bNAbs are identical in terms of their breadth, potency, a...
Autores principales: | Mayer, Bryan T., deCamp, Allan C., Huang, Yunda, Schiffer, Joshua T., Gottardo, Raphael, Gilbert, Peter B., Reeves, Daniel B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084525/ https://www.ncbi.nlm.nih.gov/pubmed/35385469 http://dx.doi.org/10.1371/journal.pcbi.1010003 |
Ejemplares similares
-
Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
por: Williamson, Brian D., et al.
Publicado: (2023) -
Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016) -
Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023) -
Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials
por: Reeves, Daniel B., et al.
Publicado: (2020) -
Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1
por: LaMont, Colin, et al.
Publicado: (2022)